Table 1.

Proportions of patients found to have a ‘Response to Treatment’ per treatment group using a threshold of −0.3

Dosing regimen	Total Number of patients	Patients with “Response to Treatment”
BZN—150 mg for 4 Weeks	30	26 (86.67%)
BZN—300 mg for 2 Weeks	29	25 (86.21%)
BZN—300 mg for 4 Weeks	28	27 (96.43%)
BZN—300 mg for 8 Weeks	28	27 (96.43%)
BZN—150 mg + E1224 for 4 Weeks	27	22 (81.48%)
BZN—300 mg + E1224 for 8 Weeks	29	23 (79.31%)
Placebo	30	10 (33.33%)

BZN Benznidazole; (1) BZN—150 mg for 4 Weeks: samples collected from individuals treated with 150 mg of Benznidazole daily for 4 weeks; (2) BZN—300 mg for 2 Weeks: samples collected from individuals treated with 300 mg of Benznidazole daily for 2 weeks; (3) BZN—300 mg for 4 Weeks: samples collected from individuals treated with 300 mg of Benznidazole daily for 4 weeks; (4) BZN—300 mg for 8 Weeks: samples collected from individuals treated with 300 mg of Benznidazole daily for 8 weeks; (5) BZN—150 mg + E1224 for 4 Weeks: samples collected from individuals treated with 150 mg of Benznidazole daily for 4 weeks plus fosravuconazole; (6) BZN—300 mg + E1224 for 8 Weeks: samples collected from individuals treated with 150 mg of Benznidazole daily for 8 weeks plus fosravuconazole and (7) Placebo: samples collected from individuals treated with Placebo. The proportions of patients were calculated from the slope of −0.025 times the 12 month period, at a log ratio threshold of the DF₅₀ of −0.3.